Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $163.96M.
ENTERPRISE VALUE (EV)
$163.96M
EyePoint Pharmaceuticals, Inc.
Market Cap
$265.78M
Enterprise Value (EV)
$163.96M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| EyePoint Pharmaceuticals, Inc. (EYPT) | $265.78M | $163.96M |
| SAB Biotherapeutics, Inc. (SABS)vs › | $266.59M | $263.46M |
| Fate Therapeutics, Inc. (FATE)vs › | $266.92M | $310.17M |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | $251.06M |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | $230.22M |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | $143.39M |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $270.80M | $71.09M |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $271.81M | $238.76M |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | $111.07M |
Market Cap
$265.78M
Total Debt
$0.00
Cash
$101.82M
Enterprise Value
$163.96M
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Why use EV instead of Market Cap?
